# US 2012/0251452 A1 · Apparatus and method for identifying one or more amyloid beta plaques in a plurality of discrete oct retinal layers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251452 A1
- Document ID: US20120251452A1
- Status: Published application
- Kind: A1
- Application number: 13/433,139
- Filed: 2012-03-28
- Published: 2012-10-04
- Earliest claimed: 2011-03-29
- Assignees: NeuroVision Imaging LLC
- Inventors: Steven Roger Verdooner
- Web page: https://patentgrep.com/patent/US20120251452A1

## CPC

- A61B 3/102: {for optical coherence tomography [OCT]}
- A61B 5/0066: {Optical coherence imaging}
- A61B 5/0071: {by measuring fluorescence emission}
- A61K 49/0021: {the fluorescent group being a small organic molecule}
- A61B 2576/026: for the brain
- G16H 30/40: for processing medical images, e.g. editing
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The present invention is an apparatus to produce an OCT of an eye or a brain of a patient to identify one or more plaques in a plurality of discrete OCT retinal layers. The present invention also includes a plurality of methods for identifying one or more plaques in a plurality of discrete OCT retinal layers that can include a contrast agent and a normative database.

## Claims

### Claim 1

An apparatus to produce an image of an eye of a patient to identify one or more amyloid beta plaques and amyloid containing drusen in a plurality of discrete OCT retinal layers, comprising:
an OCT system; and
a computer system that processes data and controls said apparatus that is in communication with said OCT system.

### Claim 2 (depends on 1)

The apparatus according to claim 1, wherein said computer system is a compact computer, an embedded computer or a tablet computer.

### Claim 3 (depends on 1)

The apparatus according to claim 1, wherein said apparatus is utilized in combination with one or more contrast agents.

### Claim 4 (depends on 3)

The apparatus according to claim 3, wherein said one or more contrast agents is one or more selected from the group consisting of curcumin, one or more curcumin derivatives, Thioflavin S, one or more Thioflavin derivatives, Thioflavin T, one or more Thioflavin T derivatives, Congo Red, one or more Congo Red derivatives, methoxy-X04, Pittsburgh CompoundB (PiB), DDNP or Chrysamine-G.

### Claim 5 (depends on 1)

The apparatus according to claim 1, wherein said apparatus is utilized in combination with one or more components that are selected from the group consisting of a spectrometer, a fluorescence microscope, a stereomicroscope, a mercury arc lamp, a variable wavelength light source, a xenon arc lamp, an LED light source, a tunable light source or swept source, a CCD gated camera, a color digital camera, an acoustic-optic tunable filter-based spectral image acquisition system, a plurality of adaptive optics, an imaging software module and any combinations thereof.

### Claim 6 (depends on 1)

The apparatus according to claim 1, wherein said image is an amyloid-beta plaque image, an amyloid image or an amyloid-beta peptide image that resides within said discrete OCT retinal layers.

### Claim 7 (depends on 1)

The apparatus according to claim 1, wherein said image is an amyloid-beta containing drusen image, an amyloid image or an amyloid-beta peptide image that resides within said discrete OCT retinal layers.

### Claim 8 (depends on 6)

The apparatus according to claim 6, wherein said apparatus generates said amyloid-beta plaque image, said amyloid image or said amyloid-beta peptide image by a spectral signature.

### Claim 9 (depends on 1)

The apparatus according to claim 1, wherein said apparatus performs a maximum and minimum intensity projection to define a volume of interest of a specific', region of interest and one or more discrete retinal layers.

### Claim 10

A method for identifying one or more amyloid beta plaques and amyloid containing drusen in a plurality of discrete OCT retinal layers, comprising the steps of:
identifying one or more A[beta] peptides located above a retinal pigment epithelium thereby differentiating said one or more A[beta] peptides from said drusen;
imaging said mammal's retina with an OCT system, a multispectral, a hyperspectral imaging or an Autofluorescence imaging device;
examining said images of said A[beta] peptides;
quantifying an increase or a decrease of said A[beta] peptides in said mammal's retina; and
rendering a prognosis based upon a level of said A[beta] peptides in the mammal's retina based on identifying one or more plaques in a plurality of discrete OCT retinal layers above said retinal pigment epithelium.

### Claim 11 (depends on 9)

The method according to claim 9, wherein said imaging said mammal's retina with said OCT, said multispectral, said hyperspectral imaging or said Autofluorescence imaging device detects possible amyloid in said mammal's retina and brain.

### Claim 12 (depends on 9)

The method according to claim 9, wherein said rendering includes evaluating one or more discrete locations of said one or more plaques in said one or more discreet locations of said one or more retinal layers, above said retinal pigment epithelium, as differentiated from said drusen which reside in or below said retinal pigment epithelium.

### Claim 13

A method for identifying one or more amyloid beta plaques and amyloid containing drusen in a plurality of discrete OCT retinal layers with a contrast agent and a normative database, comprising the steps of:
administering and staining a plurality of A[beta] peptides;
imaging said mammal's retina with an OCT system by identification of a spectral signature and retinal layer segmentation of amyloid in an OCT data set or one or more other modalities;
examining said images of said stained A[beta] peptides;
quantifying an increase or a decrease of said stained A[beta] peptides in said mammal's retina; and
rendering a prognosis based upon a level of said stained A[beta] peptides in said mammal's retina identifying said one or more plaques in said discrete OCT retinal layers.

### Claim 14 (depends on 12)

The method according to claim 12, wherein said modalities include varying one or more wavelengths of said OCT system and analyzing a generated signal to derive an amyloid signal.

### Claim 15 (depends on 13)

The method according to claim 13, wherein said signals are generated with said OCT system and a multispectral confocal and one or more optical imaging techniques.

### Claim 16 (depends on 13)

The method according to claim 13, wherein said signals are generated with one or more image and OCT layer segmentation techniques.

### Claim 17 (depends on 13)

The method according to claim 13, wherein said signals are generated from said one or more optical imaging techniques exclusively using said one or more wavelengths.

### Claim 18 (depends on 13)

The method according to claim 13, wherein said signals are generated from an exclusive OCT identification of deposit and layer segmentation.

### Claim 19 (depends on 13)

The method according to claim 13, wherein said signals are generated from an exclusive hyperspectral imaging.

### Claim 20 (depends on 13)

The method according to claim 13, wherein said signals are generated from exclusive multi-spectral imaging.

### Claim 21 (depends on 13)

The method according to claim 13, wherein said signals are generated from autofluorescence.

### Claim 22 (depends on 12)

The method according to claim 12, wherein said spectral signature of said amyloid is obtained by spectral analysis and image processing.

### Claim 23 (depends on 12)

The method according to claim 12, wherein said amyloid is generated with said contrast agent to be analyzed.

### Claim 24 (depends on 22)

The method according to claim 22, wherein said contrast agent is one or more selected from the group consisting of curcumin, one or more curcumin derivatives, Thioflavin S, one or more Thioflavin derivatives, Thioflavin T, one or more Thioflavin T derivatives, Congo Red, one or more Congo Red derivatives, methoxy-X04, Pittsburgh CompoundB (PiB), DDNP or Chrysamine-G.

### Claim 25 (depends on 12)

The method according to claim 12, wherein said OCT data set is compared to one or more other OCT data sets in said normative database and a subsequent disease state and a subsequent normal state is determined based on a comparison of said normative database and a location within said retina compared with one or more other disease states.
